Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Fineline Cube Feb 25, 2026
Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Fineline Cube Feb 25, 2026
Company Deals

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

Fineline Cube Feb 25, 2026
Company Deals

Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development

Fineline Cube Feb 25, 2026
Company Deals

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint

Fineline Cube Feb 25, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

Fineline Cube Feb 25, 2026
Company Drug

Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD

Fineline Cube Feb 25, 2026
Policy / Regulatory

Shanghai Aims to Become Capital Market Hub for High-Quality Science and Innovation Companies

Fineline Cube Aug 1, 2024

The Shanghai municipal government has unveiled a comprehensive set of measures designed to enhance the...

Company Deals Legal / IP

Sirnaomics Ltd Forms JV with Gore Range Capital to Pioneer Medical Aesthetics Innovations

Fineline Cube Aug 1, 2024

Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company specializing in RNAi therapeutics, has announced the formation...

Company Medical Device

MicroPort Scientific’s Bioabsorbable Stent System Gains NMPA Nod for Ischemic Heart Disease Treatment

Fineline Cube Aug 1, 2024

Shanghai-based medical device conglomerate MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...

Company

HutchMed Reports 2024 H1 Financials with Mixed Results Amid Strategic Focus on R&D and Commercial Efficiency

Fineline Cube Aug 1, 2024

China-based HutchMed (NASDAQ: HCM) has released its financial report for the first half of 2024,...

Company Drug

Tonghua Dongbao Pharmaceuticals Launches Phase III Clinical Trial for Semaglutide Biosimilar in China

Fineline Cube Aug 1, 2024

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the commencement of a...

Company Deals

Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program

Fineline Cube Aug 1, 2024

China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA...

Company Deals

Pfizer Enters Multi-Year R&D Collaboration with Telescope Innovations to Leverage AI and Robotics

Fineline Cube Aug 1, 2024

Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has entered into a multi-year collaborative...

Company

GSK Reports Q2 2024 Earnings with 13% Growth, Vaccines Unit Sees Mixed Results

Fineline Cube Aug 1, 2024

UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has reported its financial results for...

Company

Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches

Fineline Cube Aug 1, 2024

Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...

Company Drug Policy / Regulatory

NICE and AstraZeneca Fail to Reach Agreement on Enhertu Reimbursement for NHS

Fineline Cube Aug 1, 2024

The UK’s National Institute for Health and Care Excellence (NICE) has announced that negotiations with...

Policy / Regulatory

Shanghai Unveils Comprehensive Measures to Strengthen Biopharmaceutical Industry

Fineline Cube Aug 1, 2024

The Shanghai municipal government has issued a comprehensive set of measures aimed at bolstering the...

Company

Takeda Reports 3.7% YOY Revenue Growth in Q1 2023 Fiscal Year with Priority Products Driving Sales

Fineline Cube Aug 1, 2024

Japan-based multinational Takeda (TYO: 4502) has released its financial report for the fiscal year 2023...

Company Drug

BioNTech’s mRNA Cancer Immunotherapy BNT111 Achieves Primary Endpoint in Phase II Trial

Fineline Cube Jul 31, 2024

Germany-based BioNTech SE (NASDAQ: BNTX) has announced that its mRNA cancer immunotherapy BNT111, in combination...

Company

Pfizer Inc. Reports Q2 2024 Earnings with First Positive Growth Since Q4 2022 Peak

Fineline Cube Jul 31, 2024

Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has announced its financial results for...

Company

Merck’s Q2 2024 Earnings Miss Estimates as China Market Downturn Surprises

Fineline Cube Jul 31, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has reported its financial results for the...

Company Drug

FibroGen Inc. Enters Restructuring Mode After Late-Stage Trial Failures for Pamrevlumab

Fineline Cube Jul 31, 2024

US-based biotechnology company FibroGen Inc. (NASDAQ: FGEN), which maintains significant operations in China, is initiating...

Company Deals

National Comprehensive Cancer Network Renews Partnership with Medlive for Oncology Guidelines Access in China

Fineline Cube Jul 31, 2024

The National Comprehensive Cancer Network (NCCN), a leading non-profit academic organization in the US, has...

Policy / Regulatory

China’s NHSA and NHC to Integrate Village Clinics into Basic Medical Insurance System

Fineline Cube Jul 31, 2024

The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC) of China have...

Company Deals

Shenzhen-Based Synthetica Secures Initial Funding to Advance Oncolytic Bacteria Pipeline

Fineline Cube Jul 31, 2024

Synthetica, a pioneering developer of live bacteria drugs based in Shenzhen, has announced the successful...

Policy / Regulatory

China’s NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs

Fineline Cube Jul 31, 2024

In a meeting chaired by Party Secretary and Director of the National Medical Products Administration...

Posts pagination

1 … 281 282 283 … 626

Recent updates

  • United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential
  • Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer
  • Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD
  • MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks
  • Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Company Drug

Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD

Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.